At a glance
ClinicalIndex Comparison Record- ✓Newly diagnosed or localized recurrent/oligometastatic soft tissue sarcoma candidates for radiation (≤3 lesions if oligometastatic, all to be radiated)
- ✓Intermediate-grade tumors ≥3 cm or high-grade tumors ≥1.5 cm in maximum dimension
- ✓Plans for neoadjuvant radiation (minimum 45 Gy over ≥25 fractions) and curative-intent surgery
- ✓ECOG 0-1 or Karnofsky >70%
- ✕Prior radiation to affected area
- ✕Sarcoma subtypes with established neoadjuvant chemotherapy: extra-skeletal Ewing's sarcoma, embryonal rhabdomyosarcoma, alveolar rhabdomyosarcoma (pleomorphic RMS allowed; bone sarcomas and osteosarcoma excluded)
- ✕Prior systemic therapy or radiation for this sarcoma (prior therapy for different cancer allowed)
- ✕Prior anti-PD-1, anti-PD-L1, anti-CTLA4, anti-PD-L2, or other T-cell checkpoint inhibitor agents
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of Pembrolizumab and Neoadjuvant Radiation for Large, High-Risk Soft Tissue Sarcomas
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab and Radiation Therapy for Soft Tissue Sarcoma and Recurrent Soft Tissue Sarcoma. Completed, enrolled 27 participants across 1 site.
Detailed Summary
This phase I/II trial studies pembrolizumab and radiation therapy in treating patients with intermediate or high-grade soft tissue sarcoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving pembrolizumab and radiation therapy may work better in treating patients with soft tissue sarcoma.
Study Details
Timeline
Interventions
Given IV
Undergo radiation therapy